Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis.

Author: KinkelR P, MunschauerF E

Paper Details 
Original Abstract of the Article :
In separate clinical trials, two preparations of recombinant interferon (IFN)-beta, IFN beta-1a and IFN beta-1b, reduced exacerbation rates in relapsing-remitting multiple sclerosis (RR-MS). Further, IFN beta-1a slows the progression of disability in patients with RR-MS. Although they are effective ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/s0149-2918(97)80042-2

データ提供:米国国立医学図書館(NLM)

Interferon-Beta: Managing Side Effects in Multiple Sclerosis

Multiple sclerosis (MS) is a complex neurological condition that can significantly impact an individual's life. This study explores the management of side effects associated with interferon-beta therapy in patients with relapsing-remitting multiple sclerosis (RR-MS). The authors examine the common side effects of interferon-beta therapy and provide practical strategies for minimizing these adverse reactions.

Navigating the Side Effects of Interferon-Beta

The study highlights the importance of managing side effects associated with interferon-beta therapy in RR-MS. It provides valuable insights into the common side effects, including flu-like symptoms, injection-site reactions, and transient worsening of existing MS symptoms.

Minimizing Discomfort: Practical Strategies for Managing Side Effects

The research offers practical strategies for managing side effects associated with interferon-beta therapy. It emphasizes patient education, tailored dosing, and appropriate combination therapies to minimize adverse reactions and improve patient tolerance.

Dr. Camel's Conclusion

Multiple sclerosis, like a desert mirage, can be elusive and unpredictable. Interferon-beta therapy, like a camel's hump providing sustenance during a long journey, can offer relief and management. This study helps us navigate the potential side effects of this treatment, ensuring a smoother path through the complexities of MS.

Date :
  1. Date Completed 1997-12-30
  2. Date Revised 2019-09-20
Further Info :

Pubmed ID

9385477

DOI: Digital Object Identifier

10.1016/s0149-2918(97)80042-2

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.